Methods of enhancing adoptive cell transfer immunotherapy
By combining proteins with IgG cysteine protease or IgG endoglucosidase activity, such as IdeS and EndoS, in adoptive cell transfer immunotherapy, the problem of limited CAR T cell survival and activity was addressed, improving the efficacy of the therapy and reducing the negative effects of antibody-mediated mutations.
CN116133678BActive Publication Date: 2026-06-16HANSA BIOPHARMA AB
View PDF 4 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HANSA BIOPHARMA AB
- Filing Date
- 2021-05-18
- Publication Date
- 2026-06-16
AI Technical Summary
Technical Problem
In adoptive cell transfer immunotherapy, the survival and sustained activity of CAR T cells are limited by pre-existing antibody-mediated effector mechanisms, affecting the efficacy of the therapy.
Method used
Combined administration of proteins with IgG cysteine protease or IgG endoglucosidase activity, such as IdeS and EndoS, can remove or inactivate antibodies that affect CAR T cells, thereby reducing antibody-mediated effector function.
Benefits of technology
It improved the survival and activity of CAR T cells, enhanced the therapeutic effect of adoptive cell transfer immunotherapy, and reduced antibody-mediated complement fixation, phagocytosis, and receptor activation-induced cell death.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN116133678B_ABST
Abstract
The present invention relates to methods of enhancing adoptive cell transfer immunotherapy by administering a protein having IgG cysteine protease or IgG endoglycosidase activity.
Need to check novelty before this filing date? Find Prior Art